Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy Meeting Abstract
| Authors: | Da Silva, I. P.; Ahmed, T.; Lo, S.; Reijers, I. L. M.; Weppler, A.; Warner, A. B.; Patrinely, J. R.; Serra-Bellver, P.; Lebbe, C.; Mangana, J.; Nguyen, K.; Zimmer, L.; Ascierto, P. A.; Stout, D.; Lyle, M.; Klein, O.; Gerard, C. L.; Blank, C. U.; Menzies, A. M.; Long, G. V. |
| Abstract Title: | Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 504s |
| Language: | English |
| ACCESSION: | WOS:000560368300109 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.10005 |
| Notes: | Meeting Abstract: 10005 -- Source: Wos |
